FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagehl7.fhir.us.central-cancer-registry-reporting.r4b
Resource TypeMedicationAdministration
IdMedicationAdministration-cancer-related-medication-administration-example.json
FHIR VersionR4B

Resources that use this resource

No resources found


Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source

Narrative

status: completed

category: Outpatient

medication: rxnorm 1790099 doxorubicin hydrochloride 20 MG per 10 ML Injection

subject: Amy Shaw

effective: 2018-04-22

Performer: Joseph Nichols

reasonReference: Condition-primary-cancer-condition-breast

authoredOn: 2018-04-12

note: doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects.

Route: SNOMED 47625008 Intravenous route (qualifier value)

Dose: 105.96 mg


Source1

{
  "resourceType": "MedicationAdministration",
  "id": "cancer-related-medication-administration-example",
  "meta": {
    "profile": [
      "http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-administration"
    ]
  },
  "text": {
    "status": "extensions",
    "div": "<!-- snip (see above) -->"
  },
  "status": "completed",
  "category": {
    "coding": [
      {
        "system": "http://terminology.hl7.org/CodeSystem/medication-admin-category",
        "code": "outpatient"
      }
    ]
  },
  "medicationCodeableConcept": {
    "coding": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "code": "1790099",
        "display": "10 ML doxorubicin hydrochloride 2 MG/ML Injection"
      }
    ]
  },
  "subject": {
    "reference": "Patient/example"
  },
  "effectiveDateTime": "2018-04-22",
  "performer": [
    {
      "actor": {
        "reference": "Practitioner/1"
      }
    }
  ],
  "reasonReference": [
    {
      "reference": "Condition/primary-cancer-condition-breast"
    }
  ],
  "note": [
    {
      "authorReference": {
        "reference": "Practitioner/1"
      },
      "time": "2018-04-22",
      "text": "doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects."
    }
  ],
  "dosage": {
    "route": {
      "coding": [
        {
          "system": "http://snomed.info/sct",
          "code": "47625008",
          "display": "Intravenous route (qualifier value)"
        }
      ]
    },
    "dose": {
      "value": 105.96,
      "unit": "mg",
      "system": "http://unitsofmeasure.org",
      "code": "mg"
    }
  }
}